MedWatch

Analyst: Positive results from Ambu's Duodeno 1.5 reflected in Ambu shares

On Monday, Ambu reported that 59 of 60 procedures completed with its improved duodenoscope, the Ascope Duodeno 1.5, were successful in a recent clinical test. An analyst from Sydbank sees the rewards in Ambu's share price.

Photo: Sydbank/PR

Today's positive results from Ambu's clinical study with its new and improved duodenoscope product, the Ascope Duodeno 1.5, have been received well by investors, who have sent Ambu's share price up, as observed by Senior Equity Analyst at Sydbank Søren Løntoft Hansen.

On Monday morning, Ambu shares have increased in price by 5.4 percent to total DKK 200.1 (USD 30,4) on the stock exchange in Copenhagen.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs